PreludeDx's Breakthrough Study Reveals DCISionRT® Enhances DCIS Treatment Decisions
PreludeDx's Groundbreaking Study on DCISionRT®
On July 31, 2025, PreludeDx™, a pioneering company in breast cancer diagnostics, made an important announcement regarding a study published in the International Journal of Radiation Oncology, Biology, Physics, often referred to as the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.